title: Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding.
authors.affiliation: Dr. Hervé Quintard, MD, PhD, Intensive Care Unit, Hopital Pasteur 2, CHU NICE, 30 voie romaine, 06000 Nice, France, Tel.: +33 492033300, E-mail: quintard.h@chu-nice.fr.
authors.forename: Hervé
authors.initials: H
authors.lastname: Quintard
authors.forename: Delphine
authors.initials: D
authors.lastname: Viard
authors.forename: Milou-Daniel
authors.initials: MD
authors.lastname: Drici
authors.forename: Caroline
authors.initials: C
authors.lastname: Ruetsch
authors.forename: Charles Marc
authors.initials: CM
authors.lastname: Samama
authors.forename: Carole
authors.initials: C
authors.lastname: Ichai
mesh_terms: D058186:Acute Kidney Injury / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000931:Antidotes / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000991:Antithrombins / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D000069604:Dabigatran / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D006470:Hemorrhage / Q000097:blood / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy*; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D008297:Male; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000931:Antidotes; D000991:Antithrombins; C000594745:idarucizumab; D000069604:Dabigatran